Timothy A. Herring

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

Cornelia L. Trimble, Matthew P. Morrow, Kimberly A. Kraynyak et al. · The Lancet · 2015 · 714 citations

Medicine, Immunology, Oncology +17

Immunogenicity of a DNA vaccine candidate for COVID-19

Trevor R.F. Smith, Ami Patel, Stephanie Ramos et al. · Nature Communications · 2020 · 640 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL

Prakash Bhuyan, Michael Dallas, Kim Kraynyak et al. · Human Vaccines & Immunotherapeutics · 2020 · 52 citations · Full text

Medicine, Gynecology, Oncology +17

Development and Validation of the Influenza Intensity and Impact Questionnaire (FluiiQ™)

Richard H. Osborne, Josephine M. Norquist, Gerald R. Elsworth et al. · Value in Health · 2011 · 47 citations · Full text

Medicine, Infectious Diseases, Preventive Medicine +6

Lyme disease knowledge, beliefs, and practices of New Hampshire primary care physicians.

Julie Magri, Melissa T Johnson, Timothy A. Herring et al. · PubMed · 2003 · 29 citations

Veterinary Medicine, Family Medicine, Infectious Diseases +15